Cargando…
Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine
Background: In the metastatic setting, cancer patients may not benefit from standard care regimes and their diseases undergo drug resistance due to tumour cell heterogeneity and genomic landscape complexity. In recent years, there have been several attempts to personalise the diagnostic-therapeutic...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607087/ https://www.ncbi.nlm.nih.gov/pubmed/37892804 http://dx.doi.org/10.3390/jcm12206666 |